Several people out in my team with COVID. (None serious)

--
China’s New Covid Wave Set to See 65 Million Cases a Week
https://www.cnbctv18.com/world/china-braces-for-new-covid-19-wave-with-up-to-65-million-weekly-cases-16728131.htm

XBB is expected to result in 40 million infections per week by the end of May before peaking at 65 million a month later. This comes nearly six months after Beijing dismantled its Covid Zero curbs, allowing the virus to spread rapidly among the country’s 1.4 billion residents.

(If %0.1 of people die from it it's still 40,000 dead the first month. That's the rate of COVID deaths/infection that Korea has.)

--
COVID-19 vaccines may undergo major overhaul this fall
https://www.science.org/content/article/covid-19-vaccines-may-undergo-major-overhaul-fall

Earlier this year, U.S. regulators settled on a new strategy for COVID-19 vaccines. Like the annual flu shot, the vaccines will be updated each year based on the virus’ evolution, then rolled out in the fall. Accordingly, on 15 June, advisers to the U.S. Food and Drug Administration will weigh which strain or strains of SARS-CoV-2 should make up the next iteration of vaccine, so that the agency can greenlight a version for companies to mass-produce.

Regulators may well jettison the original SARS-CoV-2 strain that emerged in China and is long extinct—but which people are still being vaccinated against today. Many scientists favor eliminating it. The ancestral strain “should go out of the formulation,” says William Messer, an infectious disease specialist and viral immunologist at Oregon Health & Science University. Last week, the World Health Organization (WHO) agreed. But other questions loom, including whether to bundle multiple virus strains into the vaccine or just one.

To date, COVID-19 vaccines have been modified only once, when a bivalent version based on both the original strain and the BA.5 Omicron variant was introduced in September 2022. Uptake was disappointing: Only 17% of people in the United States have rolled up their sleeves. (By comparison, about 50% get an annual flu shot.) Furthermore, many researchers say the bivalent vaccine packed less of a punch than it could have. The decision to preserve the ancestral strain sprang from worries that if an entirely new variant emerged, an Omicron-only vaccine might falter against it.